h.r.1254

8/7/2019 H.R.1254

1/6

I

112TH CONGRESS1ST SESSION H. R. 1254

To amend the Controlled Substances Act to place synthetic drugs in Schedule

I.

IN THE HOUSE OF REPRESENTATIVES

MARCH 30, 2011

Mr. DENT (for himself, Mr. MEEHAN, Mr. MARINO, Mr. PLATTS, Mr.BARLETTA, Mr. CUELLAR, Mrs. EMERSON, Mrs. BIGGERT, Mr.

LATOURETTE, Mr. GIBSON, Mr. STIVERS, and Mr. REED) introduced the

following bill; which was referred to the Committee on Energy and Com-

merce, and in addition to the Committee on the Judiciary, for a period

to be subsequently determined by the Speaker, in each case for consider-

ation of such provisions as fall within the jurisdiction of the committee

concerned

A BILL

To amend the Controlled Substances Act to place synthetic

drugs in Schedule I.

Be it enacted by the Senate and House of Representa-1

tives of the United States of America in Congress assembled,2

SECTION 1. SHORT TITLE.3

This Act may be cited as the Synthetic Drug Con-4

trol Act of 2011.5

VerDate Mar 15 2010 20:57 Mar 31, 2011 Jkt 099200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1254.IH H1254

8/7/2019 H.R.1254

2/6

2

HR 1254 IH

SEC. 2. ADDITION OF SYNTHETIC DRUGS TO SCHEDULE I1

OF THE CONTROLLED SUBSTANCES ACT.2

(a) CANNABIMIMETIC AGENTS.Schedule I, as set3

forth in section 202(c) of the Controlled Substances Act4

(21 U.S.C. 812(c)) is amended by adding at the end the5

following:6

(d)(1) Unless specifically exempted or unless listed7

in another schedule, any material, compound, mixture, or8

preparation which contains any quantity of9

cannabimimetic agents, or which contains their salts, iso-10

mers, and salts of isomers whenever the existence of such11

salts, isomers, and salts of isomers is possible within the12

specific chemical designation.13

(2) In paragraph (1), the term cannabimimetic14

agents15

(A) means any substance that is a cannabinoid16

receptor type 1 (CB1 receptor) agonist as dem-17

onstrated by binding studies and functional assays18

within the following structural classes:19

(i) 2-(3-hydroxycyclohexyl)phenol with20

substitution at the 5-position of the phenolic21

ring by alkyl or alkenyl, whether or not sub-22

stituted on the cyclohexyl ring to any extent.23

(ii) 3-(1-naphthoyl)indole or 3-(1-24

naphthyl)indole by substitution at the nitrogen25

atom of the indole ring, whether or not further26


8/7/2019 H.R.1254

3/6

3

HR 1254 IH

substituted on the indole ring to any extent,1

whether or not substituted on the naphthoyl or2

naphthyl ring to any extent.3

(iii) 3-(1-naphthoyl)pyrrole by substi-4

tution at the nitrogen atom of the pyrrole ring,5

whether or not further substituted in the indole6

ring to any extent, whether or not substituted7

on the naphthoyl ring to any extent.8

(iv) 1-(1-naphthylmethyl)indene by substi-9

tution of the 3-position of the indene ring,10

whether or not further substituted in the indene11

ring to any extent, whether or not substituted12

on the naphthyl ring to any extent.13

(v) 3-phenylacetylindole or 3-14

benzoylindole by substitution at the nitrogen15

atom of the indole ring, whether or not further16

substituted in the indole ring to any extent,17

whether or not substituted on the phenyl ring18

to any extent.; and19

(B) includes20

(i) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-21

hydroxycyclohexyl]-phenol (CP-47,497);22

(ii) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-23

hydroxycyclohexyl]-phenol (cannabicyclohexanol24

or CP-47,497 C8-homolog);25


8/7/2019 H.R.1254

4/6

4

HR 1254 IH

(iii) 1-pentyl-3-(1-naphthoyl)indole1

(JWH-018 and AM678);2

(iv) 1-butyl-3-(1-naphthoyl)indole (JWH-3

073);4

(v) 1-hexyl-3-(1-naphthoyl)indole (JWH-5

019);6

(vi) 1-[2-(4-morpholinyl)ethyl]-3-(1-naph-7

thoyl)indole (JWH-200);8

(vii) 1-pentyl-3-(2-9

methoxyphenylacetyl)indole (JWH-250);10

(viii) 1-pentyl-3-[1-(4-11

methoxynaphthoyl)]indole (JWH-081);12

(ix) 1-pentyl-3-(4-methyl-1-naph-13


(x) 1-pentyl-3-(4-chloro-1-naph-15


(xi) 1-(5-fluoropentyl)-3-(1-naph-17

thoyl)indole (AM2201);18

(xii) 1-(5-fluoropentyl)-3-(2-19

iodobenzoyl)indole (AM694);20

(xiii) 1-pentyl-3-[(4-methoxy)-ben-21

zoyl]indole (SR-19 and RCS-4);22

(xiv) 1-cyclohexylethyl-3-(2-23

methoxyphenylacetyl)indole (SR-18 and RCS-24

8); and25


8/7/2019 H.R.1254

5/6

5

HR 1254 IH

(xv) 1-pentyl-3-(2-1

chlorophenylacetyl)indole (JWH-203)..2

(b) OTHER DRUGS.Schedule I of section 202(c) of3

the Controlled Substances Act (21 U.S.C. 812(c)) is4

amended in subsection (c) by adding at the end the fol-5

lowing:6

(18) 4-methylmethcathinone (Mephedrone).7

(19) 3,4-methylenedioxypyrovalerone (MDPV).8

(20) 3,4-methylenedioxymethcathinone9

(methylone).10

(21) Naphthylpyrovalerone (naphyrone).11

(22) 4-fluoromethcathinone (flephedrone).12

(23) 4-methoxymethcathinone (methedrone;13

Bk-PMMA).14

(24) Ethcathinone.15

(25) 3,4-methylenedioxyethcathinone16

(ethylone).17

(26) Beta-keto-N-methyl-3,4-18

benzodioxyolybutanamine (butylone).19

(27) N,N-dimethylcathinone20

(metamfepramone).21

(28) Alpha-pyrrolidinopropiophenone (alpha-22

PPP).23

(29) 4-methoxy-alpha-24

pyrrolidinopropiophenone (MOPPP).25


8/7/2019 H.R.1254

6/6

6

HR 1254 IH

(30) 3,4-methylenedioxy-alpha-1

pyrrolidinopropiophenone (MDPPP).2

(31) Alpha-pyrrolidinovalerophenone (alpha-3

PVP).4

(32) 6,7-dihydro-5H-indeno(5,6-d)-1,3-dioxal-5

6-amine) (MDAI)..6

SEC. 3. TEMPORARY SCHEDULING TO AVOID IMMINENT7

HAZARDS TO PUBLIC SAFETY EXPANSION.8

Section 201(h)(2) of the Controlled Substances Act9

(21 U.S.C. 811(h)(2)) is amended10

(1) by striking one year and inserting 211

years; and12

(2) by striking six months and inserting 113

year.14


h.r.1254

Documents